NCT05906992View on ClinicalTrials.gov

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

January 31, 2029

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BIOLOGICAL

CT-P53

Intravenous(IV) infusion

BIOLOGICAL

US-Ocrevus

Intravenous(IV) infusion

BIOLOGICAL

EU-Ocrevus

Intravenous(IV) infusion

Trial Locations (1)

Unknown

RECRUITING

CT-P53 3.1 investigational site, Poznan

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT05906992 - A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter